Skip to main content

Table 1 Clinicopathological characteristics of the patients with EOC

From: FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma

  Mean or number Range or percentage
Age at diagnosis (years) 57 ± 11.85 16–87
Menopause status
 Pre-menopause 33 26%
 Post-menopause 94 74%
Family history of cancer
 Yes 7 5.5%
 No 120 94.5%
Preoperative CA125 level (IU/ml) 1254.51 ± 2579.66 9.53–17,980
FIGO stage
 Stage I 35 27.6%
 Stage II 9 7.1%
 Stage III 69 54.3%
 Stage IV 14 11.0%
Pathological pattern
 Serous 90 70.9%
 Mucinous 7 5.5%
 Clear cell 21 16.5%
 Endometrioid 9 7.1%
Lymphatic metastasis
 Yes 47 37.0%
 No 80 63.0%
Current status
 NED 65 51.2%
 AWD 19 15.0%
 DOD 43 33.9%
 PFS (months) 32.598 ± 23.0 4–109
 OS (months) 40.448 ± 24.5 4–109
  1. FIGO International Federation of Gynecology and Obstetrics, NED no evidence of disease, AWD alive with disease, DOD die of disease